The precision medicine market is projected to grow from USD 110.68 billion in 2025 to USD 237.28 billion by 2031, with a CAGR of 13.58%. Growth is driven by AI integration, biomarker advancements, next-gen sequencing (35%+ market share), and expanding adoption of targeted oncology therapies. North America leads the market, while Asia-Pacific emerges as a high-growth region.

The global biopharmaceutical contract manufacturing organization (CMO) market is estimated at USD 21.16 billion in 2025 and is projected to grow to USD 76.20 billion by 2035, with a CAGR of 13.67%. Growth is driven by rising biologics demand, capacity constraints among innovator firms, and increased outsourcing strategies by pharmaceutical companies. North America holds the largest market share at 43.67%, while Asia Pacific shows the fastest growth at 15.23% CAGR.

The global clinical trials support software solutions market is valued at USD 14.31 billion in 2026 and is expected to reach USD 34.15 billion by 2035, growing at a 10.15% CAGR. North America leads the market while Asia Pacific shows the fastest growth. CTMS solutions dominate by product type, cloud-based delivery leads, and CROs lead by end-user segment. Key growth drivers include increasing clinical trial complexity, adoption of decentralized trials, AI-driven analytics, and regulatory compliance demands.

The global single nucleotide polymorphism (SNP) genotyping market is valued at USD 8.08 billion in 2026 and is expected to reach USD 19.48 billion by 2034, growing at an 11.7% CAGR. North America leads the market while Asia Pacific shows the fastest growth. PCR-based genotyping dominates by technology, pharmacogenomics leads by application, and pharmaceutical companies are the primary end users. Key drivers include personalized medicine adoption, technological advancements, and increased genomics research investments.

The global bio-preservation market is projected to grow from USD 4.52 billion in 2025 to USD 44.45 billion by 2035 at a CAGR of 25.68%, driven by cell and gene therapy commercialization, cold chain expansion, and iPSC applications. North America commands 46% market share, with media consumables achieving 32% CAGR. Record FDA approvals (8 in 2024) and 23 anticipated filings in 2025 are accelerating commercial cold chain requirements.

Nvidia is positioned for continued growth in 2026 as corporate AI spending remains strong. The company is expanding beyond chip sales into advanced computing systems, including a partnership with Thermo Fisher Scientific for AI-powered lab systems in life sciences. Trading at 24x forward earnings with expected 57% earnings growth, analysts view the stock as attractively valued with potential for further upside.

The global cell therapy processing market is projected to grow from $2.7 billion in 2025 to $7.1 billion by 2030, at a CAGR of 21.4%. Growth is driven by rising demand for advanced cell therapies including CAR-T, increasing R&D investments, expanding clinical trials, and an aging population with chronic diseases. Key challenges include complex manufacturing, regulatory hurdles, and workforce shortages. North America leads the market with the highest share.

The global Adeno Associated Virus (AAV) vector manufacturing market is projected to grow from USD 2.84 billion in 2025 to USD 9.87 billion by 2035, at a CAGR of 13.4%. Growth is driven by increased clinical trials, regulatory approvals of AAV-based gene therapies, technological innovations in manufacturing processes, and rising demand from pharmaceutical companies and CDMOs. North America leads the market while Asia Pacific shows the fastest growth rate.

A comprehensive market research report on over-the-counter and direct-to-consumer infectious disease diagnostics forecasts significant growth through 2029, driven by rapid testing technologies, privacy concerns, and digital accessibility. The report analyzes market trends across 15 countries, covering respiratory, STD, UTI, and other infectious disease testing channels, with profiles of 70+ diagnostic companies.

The global chromatography market is projected to grow from USD 10.03 billion in 2025 to USD 13.69 billion by 2031 at a CAGR of 5.32%, driven by expanding R&D in pharma/biotech and strict food safety regulations. However, high capital costs limit adoption among smaller entities. Emerging trends include green chromatography and AI-powered method optimization.

Thermo Fisher Scientific reported Q4 2025 adjusted EPS of $6.57, beating expectations of $6.45, with quarterly sales of $12.22 billion up 7% YoY. The company projects 2026 revenue growth of 4-6% and adjusted EPS of $24.22-$24.80, up 6-8%. The pending $8.875 billion Clario acquisition could add 20-25 cents to 2026 EPS. However, shares fell 3.2% following the announcement.

The global medical radiation detection devices market is projected to grow at ~7% CAGR through 2032, driven by rising cancer incidence, increased diagnostic imaging adoption, and stricter radiation safety regulations. North America leads the market, with Geiger-Müller counters as the largest product segment. Key players include Thermo Fisher Scientific, Ludlum Measurements, Mirion Technologies, and Canon Inc.